Man Group’s Spyre Therapeutics SYRE Stock Holding History

Man Group’s Portfolio SYRE Stock Details SYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$685K	Sell	7,714 -1,832	-19%	-$134K	﹤0.01%	1974
2026 Q1	$482K	Buy	+9,546	New	+$360K	﹤0.01%	2090
2025 Q3	–	Sell	-10,843	Closed	-$162K	–	2457
2025 Q2	$162K	Buy	+10,843	New	+$160K	﹤0.01%	2098
2022 Q4	–	Sell	-1,379	Closed	-$18K	–	2210
2022 Q3	$18K	Buy	+1,379	New	+$17K	﹤0.01%	1941
2022 Q2	–	Hold	0	–	–	–	2012
2020 Q1	–	Sell	-1,648	Closed	-$315K	–	1870
2019 Q4	$315K	Hold	1,648	–	–	﹤0.01%	1667
2019 Q3	$317K	Sell	1,648 -2,020	-55%	-$393K	﹤0.01%	1654
2019 Q2	$628K	Buy	3,668 +64	+2%	+$11.1K	﹤0.01%	1631
2019 Q1	$725K	Sell	3,604 -1,372	-28%	-$286K	﹤0.01%	1655
2018 Q4	$932K	Sell	4,976 -7,001	-58%	-$1.49M	﹤0.01%	1471
2018 Q3	$2.87M	Sell	11,977 -1,047	-8%	-$245K	0.01%	1263
2018 Q2	$3.44M	Buy	+13,024	New	+$3.2M	0.01%	1123

Other funds holding SYRE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Man Group's SYRE Position: Q2 2026 in Review

Man Group reduced its Spyre Therapeutics (SYRE) stake by 19% in Q2 2026, selling an estimated $134K and leaving 7,714 shares worth $685K. The position accounts for ﹤0.01% of the portfolio, ranked #1974.

Man Group first reported a position in SYRE in Q2 2018 and has held it in 11 quarters since. The position peaked at $3.44M in Q2 2018. 266 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

Man Group held 7,714 shares of Spyre Therapeutics worth $685K as of Q2 2026.
Man Group sold 1,832 Spyre Therapeutics shares in Q2 2026, an estimated $134K.
Spyre Therapeutics made up ﹤0.01% of Man Group's portfolio in Q2 2026, its #1974 holding.
Man Group first reported a position in Spyre Therapeutics in Q2 2018 and has held it in 11 quarters since.
Man Group's Spyre Therapeutics position peaked at $3.44M in Q2 2018.
266 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Man Group's 13F filing for Q2 2026, filed 14 Aug 2026.